A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ForSight Vision5, Inc.

Criteria

Inclusion Criteria:

• Written informed consent

• Primary open-angle glaucoma or ocular hypertension in both eyes

• Best-corrected distance vision of 20/100 or better

• Stable visual field

Exclusion Criteria:

• Cup-to-disc ratio greater than 0.8

• Laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12 months

• Corneal refractive surgery within prior 6 months

• Past history of any incisional surgery for glaucoma at any time

• Corneal abnormalities that would interfere with tonometry readings

• Current participation in an investigational drug or device study or participation in such a study within 30 days of screening